Patents by Inventor Richard Beard

Richard Beard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7638648
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: December 29, 2009
    Assignee: Allergan Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • Patent number: 7468391
    Abstract: The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: December 23, 2008
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Rong Yang, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Roshantha A. Chandraratna
  • Publication number: 20080004455
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Application
    Filed: March 23, 2007
    Publication date: January 3, 2008
    Applicant: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha Chandraratna
  • Patent number: 7226951
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: June 5, 2007
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Yin Tsang, Ling Li, Janet A. Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha A. Chandraratna
  • Publication number: 20060055664
    Abstract: A unified user input device is provided. The input device may include keys normally provided as part of a general purpose alphanumeric computer keyboard. In addition, a positional controller is provided. Both the conventional alphanumeric keys and the positional controller are associated with the same device platform. Additionally, special function keys may also be provided in association with the positional controller. Signals encoding the selection of an alphanumeric key, a control input, or a special function key are communicated to an interconnected computer using a common, conventional keyboard connection, and a common signaling protocol.
    Type: Application
    Filed: September 13, 2004
    Publication date: March 16, 2006
    Inventors: Mark Repetto, Gregory Danaha, Richard Beard
  • Publication number: 20050187298
    Abstract: The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
    Type: Application
    Filed: December 13, 2004
    Publication date: August 25, 2005
    Applicant: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Rong Yang, Liming Wang, Xiaoxia Liu, Kwok-Yin Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Roshantha Chandraratna
  • Publication number: 20050176689
    Abstract: Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.
    Type: Application
    Filed: December 16, 2004
    Publication date: August 11, 2005
    Inventors: Jayasree Vasudevan, Liming Wang, Xiaoxia Liu, Kwok Tsang, Ling Li, Janet Takeuchi, Thong Vu, Richard Beard, Smita Bhat, Vidyasagar Vuligonda, Roshantha Chandraratna
  • Publication number: 20050096380
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of transiently increasing triglyceride levels and reducing serum thyroxine levels.
    Type: Application
    Filed: October 29, 2003
    Publication date: May 5, 2005
    Inventors: Richard Beard, Tien Duong, Janet Takeuchi, Ling Li, Kwok Tsang, Xiaoxia Liu, Jayasree Vasudevan, Liming Wang, Santosh Sinha, Haiqing Yuan, Roshantha Chandraratna
  • Publication number: 20050004165
    Abstract: Methods for modulating the activity of the mammalian BAR/FXR receptor. The methods include methods of treating a hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds able to modulate an activity characteristic of the BAR/FXR receptor. Other methods include a method of treating colon cancer in a mammal comprising administering a compound having a BAR/FXR antagonistic activity.
    Type: Application
    Filed: August 3, 2004
    Publication date: January 6, 2005
    Inventors: Barry Forman, Richard Beard, Isabelle Dussault, Roshantha Chandraratna
  • Patent number: 6620963
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification, which bind specifically or selectively to to RAR&agr; retinoid receptors.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: September 16, 2003
    Assignee: Allergan, Inc.
    Inventors: Tien T. Duong, Richard Beard, Roshantha A. Chandraratna
  • Patent number: D796582
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: September 5, 2017
    Inventor: Richard Beard
  • Patent number: D848560
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 14, 2019
    Inventor: Richard Beard
  • Patent number: D892248
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: August 4, 2020
    Inventor: Richard Beard